Ottawa, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The global subcutaneous biologics market size was valued at USD 1.89 billion in 2024 and is predicted to hit around USD 5.37 billion by 2034, rising at a ...

The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection. The agent (Tecentriq Hybreza, ...

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

A subcutaneous injection, or shot, enters the fatty tissues just beneath the skin. It is shallower than an injection into muscle tissue. Healthcare professionals often use subcutaneous injections for ...

Castration-resistant prostate cancer (CRPC) is still a lethal disease even after the development of a new generation of hormonal drugs or chemotherapy, and thus the development of novel therapeutic ...